0001415889-24-016010.txt : 20240607 0001415889-24-016010.hdr.sgml : 20240607 20240607164234 ACCESSION NUMBER: 0001415889-24-016010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240327 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaye Edward M. MD CENTRAL INDEX KEY: 0001522780 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 241030265 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY CITY: BOTHELL STATE: WA ZIP: 98011 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 4 1 form4-06072024_080631.xml X0508 4 2024-03-27 0001623526 Stoke Therapeutics, Inc. STOK 0001522780 Kaye Edward M. MD C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 true true false false CEO 0 Employee Stock Option (Right to Buy) 14.17 2024-03-27 4 A 0 159000 0 A 2034-03-26 Common Stock 159000 159000 D Restricted Stock Units 2024-03-27 4 A 0 105000 0 A 2028-03-15 Common Stock 105000 105000 D The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. /s/ Jonathan Allan, Attorney-in-Fact 2024-06-07